PTC Therapeutics Q1 2020 Earnings Report
Key Takeaways
PTC Therapeutics reported a 27% year-over-year revenue growth in Q1 2020, reaching $68.3 million. The company highlighted the growth of its DMD franchise and positive results from risdiplam clinical trials. Due to the uncertainty of the duration and severity of the COVID-19 impact, PTC withdrew financial guidance for the 2020 fiscal year.
Total revenues for Q1 2020 were $68.3 million, a 27% increase year-over-year.
Translarna net product revenues reached $40.5 million in Q1 2020.
Emflaza net product revenues were $27.5 million for the first quarter of 2020.
PTC anticipates results from the U.S. Translarna dystrophin study in the third quarter of 2020.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Forward Guidance
Due to the uncertainty with respect to the duration, nature and extent of impacts of the COVID-19 pandemic and responsive measures relating thereto, we cannot be certain that the pandemic will not cause us to experience further delays to the timelines set forth above or other negative additional impacts.